In last trading session, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) saw 1.59 million shares changing hands with its beta currently measuring 0.47. Company’s recent per share price level of $10.05 trading at $0.02 or 0.20% at ring of the bell on the day assigns it a market valuation of $1.74B. That closing price of IOVA’s stock is at a discount of -178.21% from its 52-week high price of $27.96 and is indicating a premium of 38.51% from its 52-week low price of $6.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.22 million shares which gives us an average trading volume of 3.09 million if we extend that period to 3-months.
For Iovance Biotherapeutics Inc. (IOVA), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.90. Splitting up the data highlights that, out of 14 analysts covering the stock, 0 rated the stock as a Sell while 2 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.61 in the current quarter.
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) trade information
Upright in the green during last session for gaining 0.20%, in the last five days IOVA remained trading in the red while hitting it’s week-highest on Friday, 09/16/22 when the stock touched $10.05 price level, adding 14.4% to its value on the day. Iovance Biotherapeutics Inc.’s shares saw a change of -47.35% in year-to-date performance and have moved -15.33% in past 5-day. Iovance Biotherapeutics Inc. (NASDAQ:IOVA) showed a performance of -14.40% in past 30-days. Number of shares sold short was 19.94 million shares which calculate 3.79 days to cover the short interests.
Iovance Biotherapeutics Inc. (IOVA) estimates and forecasts
Statistics highlight that Iovance Biotherapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -39.31% of value to its shares in past 6 months, showing an annual growth rate of -13.45% while that of industry is 1.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -15.10% in the current quarter and calculating -12.70% decrease in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -3.80% during past 5 years.
Iovance Biotherapeutics Inc. is more likely to be releasing its next quarterly report between February 23 and February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Iovance Biotherapeutics Inc. (NASDAQ:IOVA)’s Major holders
Insiders are in possession of 0.47% of company’s total shares while institution are holding 104.70 percent of that, with stock having share float percentage of 105.19%. Investors also watch the number of corporate investors in a company very closely, which is 104.70% institutions for Iovance Biotherapeutics Inc. that are currently holding shares of the company. Vanguard Group, Inc. (The) is the top institutional holder at IOVA for having 12.34 million shares of worth $205.49 million. And as of Mar 30, 2022, it was holding 7.85% of the company’s outstanding shares.
The second largest institutional holder is Perceptive Advisors Llc, which was holding about 12.2 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 7.76% of outstanding shares, having a total worth of $203.15 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Hartford Mid Cap Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 8.63 million shares of worth $95.25 million or 5.49% of the total outstanding shares. The later fund manager was in possession of 5.81 million shares on Apr 29, 2022, making its stake of worth around $88.06 million in the company or a holder of 3.70% of company’s stock.